CY1111901T1 - Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων - Google Patents

Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων

Info

Publication number
CY1111901T1
CY1111901T1 CY20111100239T CY111100239T CY1111901T1 CY 1111901 T1 CY1111901 T1 CY 1111901T1 CY 20111100239 T CY20111100239 T CY 20111100239T CY 111100239 T CY111100239 T CY 111100239T CY 1111901 T1 CY1111901 T1 CY 1111901T1
Authority
CY
Cyprus
Prior art keywords
macrocycle
medicines
discovery
spatial
specified
Prior art date
Application number
CY20111100239T
Other languages
English (en)
Inventor
Pierre Deslongchamps
Yves Dory
Mark Peterson
Kamel Benakli
Eric Marsault
Luc Ouellet
Mahesh Ramaseshan
Martin Vezina
Daniel Fortin
Ruoxi Lan
Shigui Li
Gérald Villeneuve
Hamid Hoveyda
Sylvie Beaubien
Graeme Fraser
Original Assignee
Tranzyme Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tranzyme Pharma Inc. filed Critical Tranzyme Pharma Inc.
Publication of CY1111901T1 publication Critical patent/CY1111901T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Αποκαλύπτονται καινοτόμες χωροταξικά-προσδιορισμένες μακροκυκλικές ενώσεις που περιλαμβάνουν συγκεκριμένα στοιχεία ελέγχου διαμόρφωσης. Βιβλιοθήκες των μακροκυκλικών αυτών ενώσεων χρησιμοποιούνται στη συνέχεια για την επιλογή ενός ή περισσοτέρων μακροκυκλικών ειδών τα οποία επιδεικνύουν εξειδικευμένη αλληλεπίδραση με συγκεκριμένο βιολογικό στόχο. Συγκεκριμένα, αποκαλύπτονται ενώσεις σύμφωνα με την εφεύρεση ως αγωνιστές ή ανταγωνιστές υποδοχέα της μοτιλίνης από θηλαστικό και υποδοχέα της γκρελίνης από θηλαστικό.
CY20111100239T 2003-07-31 2011-02-28 Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων CY1111901T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49124803P 2003-07-31 2003-07-31
EP04761605A EP1648922B9 (en) 2003-07-31 2004-08-02 Spatially-defined macrocyclic compounds useful for drug discovery

Publications (1)

Publication Number Publication Date
CY1111901T1 true CY1111901T1 (el) 2015-11-04

Family

ID=34115484

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100239T CY1111901T1 (el) 2003-07-31 2011-02-28 Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων

Country Status (15)

Country Link
US (3) US7452862B2 (el)
EP (3) EP1648922B9 (el)
JP (1) JP4928262B2 (el)
AT (1) ATE490264T1 (el)
AU (1) AU2004261329B2 (el)
CA (1) CA2533818C (el)
CY (1) CY1111901T1 (el)
DE (1) DE602004030344D1 (el)
DK (1) DK1648922T3 (el)
ES (1) ES2357235T7 (el)
IL (1) IL173312A0 (el)
PL (1) PL1648922T3 (el)
PT (1) PT1648922E (el)
SI (1) SI1648922T1 (el)
WO (1) WO2005012331A1 (el)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
ES2338789T3 (es) * 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US8921521B2 (en) 2003-06-18 2014-12-30 Ocera Therapeutics, Inc. Macrocyclic modulators of the Ghrelin receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP1648923B1 (en) * 2003-07-31 2008-12-31 Tranzyme Pharma Inc. Spatially-defined macrocycles incorporating peptide bond surrogates
JP5739766B2 (ja) * 2004-06-18 2015-06-24 オセラ セラピューティクス， インコーポレイテッド グレリン受容体の大環状モジュレーターの使用方法
WO2006046977A1 (en) * 2004-10-26 2006-05-04 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and methods of using the same
EP1891090A2 (en) * 2005-06-13 2008-02-27 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP2441763A1 (en) * 2005-07-26 2012-04-18 Glaxo Group Limited Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
CN101528765B (zh) 2006-09-11 2015-04-22 欧塞拉治疗有限公司 用于治疗胃肠动力障碍病症的促胃动素受体的大环拮抗剂
ES2602789T3 (es) 2007-02-09 2017-02-22 Ocera Therapeutics, Inc. Productos intermedios conectores para la síntesis de moduladores macrocíclicos del receptor de la grelina
US20080287371A1 (en) * 2007-05-17 2008-11-20 Tranzyme Pharma Inc. Macrocyclic antagonists of the motilin receptor for modulation of the migrating motor complex
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2547415T3 (es) 2009-02-27 2015-10-06 Raqualia Pharma Inc Derivados de oxiindol con actividad agonista del receptor de motilina
US9662126B2 (en) 2009-04-17 2017-05-30 Arthrosurface Incorporated Glenoid resurfacing system and method
WO2011053821A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2011105310A1 (en) * 2010-02-26 2011-09-01 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
CA2821547A1 (en) 2010-12-29 2012-07-05 Sigma-Aldrich Co. Llc Cells having disrupted expression of proteins involved in adme and toxicology processes
KR101668514B1 (ko) 2011-02-25 2016-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체
JP2015525782A (ja) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病性三環式化合物
CN103113404B (zh) * 2013-02-22 2015-09-23 广州巨元生化有限公司 一种制备4-二烃氧基膦酰基-2-甲基-2-丁烯酸烃基酯的方法
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2017049383A1 (en) 2015-09-24 2017-03-30 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
WO2017072062A1 (en) 2015-10-27 2017-05-04 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CA3024071C (en) * 2016-05-16 2023-02-21 Cyclenium Pharma Inc. Libraries of diverse macrocyclic compounds and methods of making and using the same
US20180110824A1 (en) * 2016-10-21 2018-04-26 Ocera Therapeutics, Inc. Macrocyclic Modulators of the Ghrelin Receptor
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
US11524979B2 (en) 2017-06-15 2022-12-13 University Of Washington Macrocyclic polypeptides
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
CA3127387A1 (en) * 2019-02-08 2020-08-13 Eric Marsault Neurotensinergic agonists and methods of using same preventing or treating pain

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2235377A1 (de) 1971-07-30 1973-02-08 Banyu Pharma Co Ltd 2,4-thiazol-dimethanol-carbamat und verfahren zu dessen herstellung
GB1365201A (en) 1971-07-30 1974-08-29 Banyu Pharma Co Ltd 2 4 thiazoledimethanol carbamates and 2 4-thiazoledimethanol
US3997540A (en) 1975-07-21 1976-12-14 Burroughs Wellcome Co. O [(O-piperazinocarbonyl-phenyl)-thio]-benzoates
US4382090A (en) * 1980-10-02 1983-05-03 Eli Lilly And Company N-Thiazolylmethylthioalkyl-N'alkylamidines and related compounds
US5514786A (en) * 1990-01-11 1996-05-07 Isis Pharmaceuticals, Inc. Compositions for inhibiting RNA activity
AU4761996A (en) 1995-01-20 1996-08-07 Molecumetics, Ltd. Conformationally constrained reverse-turn library and methods relating thereto
US5646285A (en) 1995-06-07 1997-07-08 Zymogenetics, Inc. Combinatorial non-peptide libraries
US5891737A (en) 1995-06-07 1999-04-06 Zymogenetics, Inc. Combinatorial non-peptide libraries
IL117426A (en) 1996-03-10 2005-09-25 Yissum Res Dev Co Synthetic pseudopeptides having osteogenic activity and pharmaceutical compositions containing the same
US5712253A (en) 1996-06-18 1998-01-27 Abbott Laboratories Macrocyclic 13-membered ring derivatives of erythromycins A and B
US6011155A (en) 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
EP1015479A4 (en) 1997-04-11 2002-07-24 Lilly Co Eli COMBINATIVE SUBSTANCE LIBRARIES OF PEPTIDOMIMETIC MACROCYCLES AND THE RELATED METHODS
US20020068301A1 (en) 1997-05-28 2002-06-06 Hung-Sen Lai Cyclic peptide libraries and methods of use thereof to identify binding motifs
US6165985A (en) * 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
CA2284459C (en) 1999-10-04 2012-12-11 Neokimia Inc. Combinatorial synthesis of libraries of macrocyclic compounds useful in drug discovery
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
JP2004504406A (ja) 2000-07-24 2004-02-12 アーダナ　バイオサイエンス　リミテッド グレリンアンタゴニスト
US6653334B1 (en) * 2002-12-27 2003-11-25 Kowa Co., Ltd. Benzoxazole compound and pharmaceutical composition containing the same
ES2338789T3 (es) * 2003-06-18 2010-05-12 Tranzyme Pharma Inc. Antagonistas macrociclicos del receptor de motilina.
US7476653B2 (en) * 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
EP1648923B1 (en) * 2003-07-31 2008-12-31 Tranzyme Pharma Inc. Spatially-defined macrocycles incorporating peptide bond surrogates
CA2535749C (en) * 2003-09-03 2011-11-01 Kowa Co., Ltd. Ppar activating compound and pharmaceutical composition containing same

Also Published As

Publication number Publication date
EP2319859B1 (en) 2013-03-27
WO2005012331A1 (en) 2005-02-10
EP2316846A3 (en) 2012-04-04
CA2533818A1 (en) 2005-02-10
ES2357235T3 (es) 2011-04-20
IL173312A0 (en) 2009-02-11
US8440851B2 (en) 2013-05-14
EP1648922A4 (en) 2006-08-23
DE602004030344D1 (de) 2011-01-13
CA2533818C (en) 2015-03-17
EP2316846A2 (en) 2011-05-04
US7452862B2 (en) 2008-11-18
DK1648922T3 (da) 2011-03-14
EP1648922B3 (en) 2012-08-15
EP2319859A2 (en) 2011-05-11
EP1648922A1 (en) 2006-04-26
US20090137817A1 (en) 2009-05-28
EP1648922B1 (en) 2010-12-01
EP2316846B1 (en) 2019-10-02
PT1648922E (pt) 2011-01-04
SI1648922T1 (sl) 2011-03-31
AU2004261329A1 (en) 2005-02-10
US20110237785A1 (en) 2011-09-29
JP4928262B2 (ja) 2012-05-09
JP2007527863A (ja) 2007-10-04
ES2357235T7 (es) 2013-02-14
EP1648922B9 (en) 2013-04-03
ATE490264T1 (de) 2010-12-15
ES2357235T8 (es) 2011-06-06
US20050137127A1 (en) 2005-06-23
AU2004261329B2 (en) 2011-10-27
US8022252B2 (en) 2011-09-20
EP2319859A3 (en) 2011-12-21
PL1648922T3 (pl) 2011-05-31

Similar Documents

Publication Publication Date Title
CY1111901T1 (el) Χωροταξικα - προσδιορισμενες μακροκυκλικες ενωσεις χρησιμες για την ανακαλυψη φαρμακων
ATE419267T1 (de) Räumlich definierte makrocyclen, die peptidbindungssurrogate enthalten
BRPI0605921A2 (pt) compostos orgánicos
DE602005010961D1 (de) Phenylcarbazole basierte Verbindungen und deren Verwendung als organische Elektroluminiszierende Vorrichtung
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
PT1969007E (pt) Composições e métodos para a produção de uma composição
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0608376A8 (pt) composição de ligação, método de uso de uma composição de ligação, e, kit de detecção
CY1107773T1 (el) Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
CL2007002100A1 (es) Compuestos derivados biciclicos que contienen nitrogeno, sus sales, solvatos y n-oxidos; composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
BRPI0518079A (pt) usos de um inibidor de mtor, de uma rapamicina, e de 42-éster de rapamicina com ácido 3-hidróxi-2- (hidroximetil) -2-metilpropiÈnico, composição farmacêutica, e, embalagem farmacêutica
NO20053708D0 (no) Sikkerhetsbeholdere for biologiske aktive forbindelser og fremgangsmate for fremstilling av denne beholderen
ATE465148T1 (de) Chemische verbindungen i
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
CL2007003693A1 (es) Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
DE60305026D1 (de) 3,4-dihydrochinolin-2(1h)-on verbindungen als nr2b rezeptor antagonisten
BRPI0507656A (pt) agentes parasiticidas
WO2005079378A3 (en) Synthetic techniques and intermediates for polyhydroxy dienyl lactones and mimics thereof
DK1522859T3 (da) On-board-kontrol for testelementer
EP1411132A3 (en) Detection of mecA-containing Staphylococcus spp.
ATE301643T1 (de) Oxazin(thi)onverbindungen als fungizide
ATE495190T1 (de) Antibiotische drosocinderivate
DK1270576T3 (da) 3-phenyl-3,7-diazabicyclo[3,3,1]nonan-forbindelser samt fremgangsmåde til fremstilling heraf og lægemidler indeholdende sådanne forbindelser